| 著者 |
Benjamin Jester, Hui Zhao, Mesfin Gewe, Thomas Adame, Lisa Perruzza, David Bolick, Jan Agosti, Nhi Khuong, Rolf Kuestner, Caitlin Gamble, Kendra Cruickshank, Jeremy Ferrara, Rachelle Lim, Troy Paddock, Colin Brady, Stacey Ertel, Mia Zhang, Michael Tasch, Tracy Saveria, David Doughty, Jacob Marshall, Damian Carrieri, Jamie Lee, Lauren Goetsch, Jason Dang, Nathaniel Sanjaya, David Fletecher, Anissa Martinez, Bryce Kadis, Kristjian Sigmar, Esha Afreen, Tammy Nguyen, Amanda Randolph, Alexandria Taber, Ashley Krzeszowski, Brittney Robinett, Fabio Grassi, Richard Guerrant, Michael Spigarelli, Ryo Takeuchi, Brian Finrow, Craig Behnke, James Roberts
|
| Abstract |
ABSTRACTArthrospira platensis (commonly known as spirulina) is a photosynthetic cyanobacterium1. It is a highly nutritious food that has been consumed for decades in the US, and even longer by indigenous cultures2. Its widespread use as a safe food source and proven scalability have driven frequent attempts to convert it into a biomanufacturing platform. But these were repeatedly frustrated by spirulina’s genetic intractability. We report here efficient and versatile genetic engineering methodology for spirulina that allows stable expression of bioactive protein therapeutics at high levels. We further describe large-scale, indoor cultivation and downstream processing methods appropriate for the manufacturing of biopharmaceuticals in spirulina. The potential of the platform is illustrated by pre-clinical development and human testing of an orally delivered antibody therapeutic against campylobacter, a major cause of infant mortality in the developing world and a growing antibiotic resistance threat3,4. This integrated development and manufacturing platform blends the safety of food-based biotechnology with the ease of genetic manipulation, rapid growth rates and high productivity characteristic of microbial platforms. These features combine for exceptionally low-cost production of biopharmaceuticals to address medical needs that are unfeasible with current biotechnology platforms.
|
